Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
Samuel R. Denmeade
Johns Hopkins Oncology Center and James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
Search for more papers by this authorXiaohui S. Lin
Johns Hopkins Oncology Center and James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
Search for more papers by this authorCorresponding Author
John T. Isaacs
Johns Hopkins Oncology Center and James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, 422 N. Bond St., Baltimore, MD 21231-1001Search for more papers by this authorSamuel R. Denmeade
Johns Hopkins Oncology Center and James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
Search for more papers by this authorXiaohui S. Lin
Johns Hopkins Oncology Center and James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
Search for more papers by this authorCorresponding Author
John T. Isaacs
Johns Hopkins Oncology Center and James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, 422 N. Bond St., Baltimore, MD 21231-1001Search for more papers by this authorAbstract
Cells possess within their epigenetic repertoire the ability to undergo an active process of cellular suicide termed programmed (or apoptotic) cell death. This programmed cell death process involves an epigenetic reprogramming of the cell that results in an energy-dependent cascade of biochemical and morphologic changes (also termed apoptosis) within the cell, resulting in its death and elimination. Although the final steps (i.e., DNA and cellular fragmentation) are common to cells undergoing programmed cell death, the activation of this death process is initiated either by sufficient injury to the cell induced by various exogenous damaging agents (e.g., radiation, chemicals, viruses) or by changes in the levels of a series of endogenous signals (e.g., hormones and growth/survival factors). Within the prostate, androgens are capable of both stimulating proliferation as well as inhibiting the rate of the glandular epithelial cell death. Androgen withdrawal triggers the programmed cell death pathway in both normal prostate glandular epithelia and androgen-dependent prostate cancer cells. Androgen-independent prostate cancer cells do not initiate the programmed cell death pathway upon androgen ablation; however, they do retain the cellular machinery necessary to activate the programmed cell death cascade when sufficiently damaged by exogenous agents. In the normal prostate epithelium, cell proliferation is balanced by an equal rate of programmed cell death, such that neither involution nor overgrowth normal occurs. In prostatic cancer, however, this balance is lost, such that there is greater proliferation than death producing continuous net growth. Thus, an imbalance in programmed cell death must occur during prostatic cancer progression. The goal of effective therapy for prostatic cancer, therefore, is to correct this imbalance. Unfortunately, this has not been achieved and metastatic prostatic cancer is still a lethal disease for which no curative therapy is currently available. In order to develop such effective therapy, an understanding of the programmed death pathway, and what controls it, is critical. Thus, a review of the present state of knowledge concerning programmed cell death of normal and malignant prostatic cells will be presented. © 1996 Wiley-Liss, Inc.
References
- 1 Wingo PA, Tong T Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45: 8–30, 1995.
- 2 Kerr JFR, Wyllie AG, Currie AR: Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26: 239–257, 1972.
- 3 Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68: 251–306, 1980.
- 4 Bowen ID, Lockshin RA: “ Cell Death in Biology and Pathology”. Chapman & Hall, London, 1981.
10.1007/978-94-011-6921-9 Google Scholar
- 5 Wyllie AH: Glucocorticoid induces in thymocytes a nuclease-like activity associated with the chromatin condensation of apoptosis. Nature 284: 555–556, 1980.
- 6 Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552–562, 1988.
- 7 Umansky SR, Korol BA, Nelipovich PA: In vivo DNA degradation in thymocytes of -irradiated or hydrocortisone-treated rats. Biochim Biophys Acta 655: 9–17, 1981.
- 8 Berges RS, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT: Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA 90: 8910–8914, 1993.
- 9 Isaacs JT: Antagonistic effect of androgen on prostatic cell death. Prostate 5: 545–557, 1984.
- 10 Berges RS, Vukanovic J, Epstein JI, Carmichel M, Cisek L, Johnson DE, Veltri RW, Walsh PH, Isaacs JT: Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1: 473–480, 1995.
- 11 Kyprianou N, Isaacs JT: Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. Prostate 11: 41–50, 1987.
- 12 English HF, Kyprianou N, Isaacs JT: Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15: 233–251, 1989.
- 13 Prins GS, Birch L, Greene GL: Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1229: 3187–3199, 1991.
- 14 Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL: Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 6: 2123–2128, 1992.
10.1210/me.6.12.2123 Google Scholar
- 15 Kyprinaou N, Isaacs JT: Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate 10: 313–324, 1987.
- 16 Kerr JFR, Searle J: Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch Cell Pathol 13: 87–102, 1973.
- 17 English HF, Drago JR, Santen RJ: Cellular response to androgen ablation and repletion in the rat ventral prostate: Autoradiography and morphometric analysis. Prostate 7: 41–51, 1985.
- 18 Coffey DS, Shimazaki J, Williams-Ashman HG: Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys 124: 184–198, 1968.
- 19 Lesser B, Bruchovsky N: The effects of testosterone, 5α-dihydrotestosterone and adenosine 3′,5′-monophosphate on cell proliferation and differentiation in rat prostate. Biochim Biophys Acta 308: 427–437, 1973.
10.1016/0005-2787(73)90336-5 Google Scholar
- 20 Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF: Androgen regulation of programmed death of normal and malignant prostatic cells. J Andrology 13: 457–464, 1992.
- 21 Kyprianou N, English HF, Isaacs JT: Activation of a Ca2+-Mg2+-dependent endonudease as an early event in castration-induced prostatic cell death. Prostate 13: 103–117, 1988.
- 22 Martikainen P, Isaacs JT: Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 17: 175–187, 1990.
- 23 Kyprianou N, Isaacs JT: Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens. Endocrinology 123: 2124–2131, 1988.
- 24 Pegg AE, Lockwood DH, Williams-Ashaman HG: Concentrations of putrescine and polyamines and their enymic synthesis during androgen-induced, prostatic growth. Biochem J 117: 17–31, 1970.
- 25 Chung LWK, Coffey DS: Biochemical characterization of prostatic nuclei I. Androgen-induced changes in nuclear proteins. Biochim Biophys Acta 247: 570–583, 1971.
- 26 Snyder RD: Polyamine depletion is associated with altered chromatin structure in HeLa cells. Biochem J 260: 697–704, 1989.
- 27 Brüne B, Hartzell P, Nicotera P, Orrenius S: Spermine prevents endonuclease activation and apoptosis in thymocytes. Exp Cell Res 195: 323, 1991.
- 28 Lazebnik YA, Kaufman SH, Desnoyers S, Poirer GG, Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346–347, 1994.
- 29 Nicholson DW, Ali A, Thornberry NA, et al: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37–43, 1995.
- 30 Fesus L, Thomazy V, Falus A: Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett 224: 104–108, 1989.
- 31 Savill JS, Dransfield I, Hogg N, Haslett C: Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 343: 170–173, 1990.
- 32 Quarmby VE, Beckman WC Jr, Wilson EM, French FS: Androgen regulation of c-myc messenger ribonudeic acid levels in rat ventral prostate. Mol Endocrinol 1: 865–874, 1987.
- 33 Buttyan R, Zaker Z, Lockshin R, Wolgemuth D: Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol 2: 650–657, 1988.
- 34 Chang C, Saltzman AG, Sorensen NS, Hiipakka RA, Liao S: Identification of glutathione S-transferase Yb1 mRNA as the androgen repressed mRNA by cDNA cloning and sequence analysis. J Biol Chem 262: 11901–11903, 1987.
- 35 Montpetit ML, Lawless KR, Tenniswood M: Androgen repressed messages in the rat ventral prostate. Prostate 8: 25–36, 1986.
10.1002/pros.2990080105 Google Scholar
- 36 Kyprianou N, Isaacs JT: Expression of transforming growth factor-β in the rat ventral prostate during castration induced programmed cell death. Mol Endocrinol 3: 1515–1522, 1989.
- 37 Furuya Y, Isaacs JT: Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology 133: 2660–2666, 1993.
- 38 Buttyan R, Olsson CA, Pintar J, Chang C, Bandyk M, Ng PY, Sawczuk IS: Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol 9: 3473–3481, 1989.
- 39 Dowd DR, MacDonald PN, Komm BS, Haussier MR, Miesfeld R: Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated apoptosis. J Biol Chem 266: 18423–18426, 1991.
- 40 Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493–501, 1992.
- 41 Stiens R, Helpap B: Regressive changes in the prostate after castration. A study using histology, morphometrics and autoradiography with special reference to apoptosis. Pathol Res Pract 172: 73–87, 1981.
- 42 Evans GS, Chandler JA: Cell proliferation studies in the rat prostate. II. The effects of castration and androgen replacement upon basal and secretory cell proliferation. Prostate 11: 339–352, 1987.
- 43 Furuya Y, Walsh JC, Lin X, Nelson WG, Isaacs JT: Androgen ablation induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology 136: 1898–1906, 1995.
- 44 Lowe S, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362: 847–849, 1993.
- 45 Crawford ED, et al: A control randomized trial of leuprolide with and without flutamide in prostatic cancer. N Engl J Med 321: 419–424, 1989.
- 46 Isaacs JT: Hormonally responsive vs unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and G rat prostatic adenocarcinoma. Cancer Res 42, 5010–5014, 1982.
- 47 Raghavan D: Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs. Semin Oncol 15: 371–389, 1988.
- 48 Shackney SE, McCormack GW, Cuchural GJ: Growth rate patterns of solid tumors and their relationship to responsiveness to therapy. Ann Intern Med 89: 107–115, 1978.
- 49 Isaacs JT, Lundmo PI: Chemotherapeutic induction of programmed cell death in non proliferating prostate cancer cells. Proc Am Assoc Cancer Res 33: 588–589, 1992.
- 50 Tubiana M, Malaise EP: Growth rate and cell kinetics in human tumors: some prognostic and therapeutic implications. In T Symington, RL Carter (eds): “ Scientific Foundation of Oncology”. Chicago: YearBook Medical Publishers, 1976, pp 126–138.
- 51 Kyprianou N, Isaacs JT: Thymine-less death in androgen independent prostatic cancer cells. Biochem Biophys Res Commun 165: 73–81, 1989.
- 52 Connor J, Sawczuk IS, Benson MC, Tomasahefsky P, O'Toole KM, Olsson CA, Buttyan R: Calcium channel antagonists delay regression of androgen-independent tissues and suppress gene activity associated with cell death. Prostate 13: 119–130, 1988.
- 53 Sells SF, Wood DP, Joshi-Barve SS, et al: Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Diff 5: 457, 1994.
- 54 Greenberg DA: Calcium channels and calcium channel antagonists. Ann Neurol 21: 317–330, 1987.
- 55 Martikainen P, Kyprianou N, Tucker RW, Isaacs JT: Programmed death of nonproliferating androgen independent prostatic cancer cells. Cancer Res 51: 4693–4700, 1991.
- 56 Tsujimota Y, Cossman J, Jaffe E, Croce C: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440–1443, 1985.
- 57 Chen-Levy S, Cleary ML: Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro. J Biol Chem 265: 4929–4933, 1990.
- 58 Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC: Investigations of the subcellular distribution of the BCL-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53: 4701–4714, 1993.
- 59 Reed JC, Cuddy M, Slabiak T, Croce CM, Nowell PC: Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 336: 259–261, 1988.
- 60 McDonnell TJ, Deane N, Platt FH, Nunes G, Jaeger U, McKearn JP, Korsmeyer SJ: Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57: 79–88, 1989.
- 61 Vaux D, Cory S, Adams J: Bcl-2 promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440–442, 1988.
- 62 Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334–336, 1990.
- 63 Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 74: 609–619, 1993.
- 64 Yin XM, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 369: 321–323, 1994.
- 65 Miyashita T, Reed JC: Bcl-2 gene transfer increase relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by gluco-corticoids and multiple chemotherapeutic drugs. Cancer Res 52: 5407–5411, 1992.
- 66 Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151–157, 1993.
- 67 Walton MI, Whysong D, O'Connor PM, et al: Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53: 1853–1861, 1993.
- 68 Hanada M, Krajewski S, Tanaka S, et al: Regulation of bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res 53: 4978–4986, 1993.
- 69 Levine B, Huang Q, Isaacs JT, et al: Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature 361: 739–742, 1993.
- 70 McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940–6944, 1992.
- 71 Colombel M, Symmans F, Gil S, et al: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390–400, 1993.
- 72 Shabaik AS, Krajewski S, Burgan A, Krajewski M, Reed JC: Bcl-2 protooncogene expression in normal, hyper-plastic, and neoplastic prostate tissue. J Urol Pathol 3: 17–27, 1995.
- 73 Isaacs JT: Role of androgens in prostatic cancer. Vitam Horm 49: 433–502, 1994.
- 74 Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT: Expression of bcl-2 and the progression of human and rodent prostate cancers. Clin Cancer Res 2: (in press), 1996.
- 75 Isaacs JT, Hukku B: Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate 13: 165–188, 1988.
- 76 Isaacs JT, Wake N, Coffey DS, Sanberg AA: Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42: 2353–2361, 1982.
- 77 Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1–6, 1994.
- 78 Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799–1805, 1994.
- 79 Navone NM, Troncoso P, Pisters LL, et al: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657–1669, 1993.
- 80 Folkman J: What is the evidence that tumors are anglogenesis-dependent? J Natl Cancer Inst 82: 4–6, 1990.
- 81 Vukanovic J, Passaniti A, Hirata T, et al: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53: 1833–1837, 1993.
- 82 Ichikawa T, Lamb JC, Christensson PJ, Hartley-Asp B, Isaacs JT: The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res 52: 3022–3028, 1992.
- 83 Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 55: 1499–1504, 1995.
- 84 Furuya Y, Isaacs JT: Proliferation-dependent vs independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate 25: 301–309, 1994.
- 85 Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT: The role of calcium pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 54: 6167–6175, 1994.
- 86 Christensen SB, Norup E, Rasmussen U: Chemistry and structure-activity relationship of the histamine secretagogue Thapsigargin and related compounds. In Krogsgaard-Larsen P, Brogger S, Christensen, Kofod H (eds): “ Natural Products and Drug Development.” 1993, pp 405–418.
- 87 Rasmussen U, Christensen SB, Sandberg F: Thapsigargin and thapsigargirin, two new histamine liberators from Thapsia garganica. L Acta Pharm Suec 15: 133, 1978.
- 88 Thastrup O, Cullen PJ, Drbak BK, Hanley MR, Dawson AP: Thapsigargin, a tumor promoter, discharges intra-cellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2+-AT-Pase. Proc Natl Acad Sci USA 87: 2466–2470, 1990.
- 89 Lytton J, Westlin M, Haley MR: Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca2+-AT-Pase family of calcium pumps. J Biol Chem 266: 17067–17071, 1991.
- 90 Christensson A, Laurell CB, Lilja H: Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755–765, 1990.
- 91 Watt KWK, Lee PJ, Timkulu TM, Chan WP, Loor R: Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83: 3166–3170, 1986.
- 92 Lilja H, Christensson C, Dahlen U, et al: Prostate-specific antigen in human serum occurs predominantly in complex with α1-antichymotzypsin. Clin Chem 37: 1618–1625, 1991.
- 93 Lilja H, Abrahamsson PA, Lundwall A: Semenogelin, the predominant protein in human semen. J Biol Chem 264: 1894–1900, 1989.
- 94 Christensen SB, Andersen A, Paulsen JCJ, Treiman M: Derivatives of thapsigargin as probes of its binding site on endoplasmic reticulum Ca2+ ATPase. FEBS 335: 345, 1993.